Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old.
Treatment of very old patients with non-Hodgkin's lymphoma remains controversial. Indeed, patients over 80 years old are usually not included in trials. We show here that addition of rituximab to reduced-dose CHOP chemotherapy seems to be a good compromise between toxicity and efficacy, allowing clinicians to treat very elderly patients with a curative intent.
Italiano
Antoine
A
Jardin
Fabrice
F
Peyrade
Frederic
F
Saudes
Laurence
L
Tilly
Herve
H
Thyss
Antoine
A
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone